linjc16/ctgov huggingface dataset:
Airway Responses Following Chlorine Gas Exposure

Study Overview
=================
Brief Summary
-----------------
To determine lung airway responses following chlorine gas exposure.

Detailed Description
-----------------
DESIGN NARRATIVE: The specific aims of the study are to determine: (1) the effects of asthma with pre-existing airway hyper reactivity on the pulmonary function and airway reactivity and inflammation responses to chlorine; (2) the effects of chlorine concentration on the pulmonary function and airway reactivity and inflammation responses to chlorine; and (3) to assess the time dynamics of the pulmonary function and airway reactivity and inflammation responses to chlorine. It is hypothesized that both airway hyperactivity and higher chlorine concentration will result in larger changes in pulmonary function and airway reactivity and inflammation responses, and that these changes will have differential time courses following chlorine exposure. This study uses two controlled human exposure experiments, utilizing a single-blind, repeated-measures, and counter- balanced design. The two subject groups for both experiments will consist of 21 individuals with no airway hyperactivity, and 21 individuals with both asthma and airway hyperactivity. In Experiment One, subjects are exposed for 15 minutes separately to each of: (1) chlorine at 0.4 ppm; (2) chlorine at 1.0 ppm; and (3) filtered air (Control). Pulmonary function and airway reactivity are measured immediately pre-exposure and 1 and 20 hours post-exposure. Airway inflammation, as determined by cellular and biochemical components from sputum-induction, is measured 65 hours pre-exposure and 20 hours post-exposure. In Experiments Two, subjects are exposed for 15 minutes separately to each of: (1) chlorine (concentration determined from Experiment One); (2) filtered air (Control). Pulmonary function and airway reactivity are measured immediately pre-exposure and at 3 and 72 hours post-exposure. Sputum-induction is performed 65 hours pre-exposure and at 3 and 72 hours post-exposure. The results of this study will provide information on a major irritant chemical relevant to occupational environments. Specially, the susceptibility of a large sub-population at increased risk, the dose-response effects, and the post-exposure time dynamics of the effects of chlorine gas will be determined. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Asthma, Lung Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
SOKARY Mobile Application With Type II Diabetes

Study Overview
=================
Brief Summary
-----------------
Android mobile application named (SOKARY)

Detailed Description
-----------------
Android mobile application named (SOKARY) which means diabetes was selected as an example of mobile health application as it has the advantage of Arabic interface, free use it allows users to record his/their blood glucose level, nutrition and physical activity, then provide the user with statistics for those readings. The application also sends notifications to the users such as medication reminders and healthy lifestyle advice.

Official Title
-----------------
Effectiveness of Using SOKARY Mobile Application on Compliance of Patient With Type II Diabetes: A Quasi- Experimental Study

Conditions
-----------------
Type II Diabetes

Intervention / Treatment
-----------------
* Device: SOKARY Mobile


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be familiar with the use of mobile health applications. Own a smartphone with an android operating system. Able to use the internet either through Wi-Fi network and\or mobile data. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Type II diabetes<br>using mobile app | Device: SOKARY Mobile<br>* Effectiveness of using SOKARY Mobile Application on compliance of patient with Type II diabetes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the patient's compliance after using SOKARY mobile app | Increase level of Patients' compliance | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mobile phone application, DM type II, EGYPT, Compliance
Nephrocalcinosis in Very Low Birth Weight Infants

Study Overview
=================
Brief Summary
-----------------
Extremely premature children benefit from specific follow-up that requires high nutritional intake and the use of specific therapies that expose them to the risk of nephrocalcinosis. Other identified risk factors are extreme prematurity and intrauterine growth restriction. The incidence of nephrocalcinosis in very premature infants is unclear, ranging from 7 to 64%. Most studies are observational and only few case-control studies can properly analyse the risk factors for nephrocalcinosis in significant populations that include only preterm infants. This nephrocalcinosis of prematurity regresses spontaneously in more than half of the cases, but has been associated with a risk of long-term complications: impaired renal function, high blood pressure, etc. This is an aggravating factor in the context of prematurity, which has been associated with an increased risk of renal impairment and hypertension in childhood and adulthood. For all these reasons, nutritional intakes and therapeutics are monitored very closely and a renal ultrasound is routinely performed at discharge at 35 weeks of corrected gestational age in all children who are born at a gestational age ≤ 32 weeks and/or birth weight ≤ 1500 g.

Official Title
-----------------
Nephrocalcinosis in Very Low Birth Weight Infants: an Observational Study

Conditions
-----------------
Infant; Premature, Light-For-Dates

Intervention / Treatment
-----------------
* Other: Renal ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newborns with a gestational age <= 32 weeks and/or birthweight <=1500g Exclusion Criteria: Newborns with kidney malformation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Renal ultrasound|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of nephrocalcinosis | Presence/absence of nephrocalcinosis will be checked by ultrasound | At week 35 of corrected gestational age |
Study of Different Types of Backache in Groups of Patients With Different Diagnoses of Degenerative Diseases

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine whether there are relations between different types of pain in groups of patients with different diagnoses of degenerative diseases of the spinal column and their related surgeries.

Detailed Description
-----------------
In the context of this work the pain of different groups of patients should be examined by means of the painDetect Questionnaire, the Roland-Morris disability questionnaire, clinical examinations and different imaging procedures. Two groups of patients are compared with each other. Group one consists of patients with osteoporotic fractures of the vertebra. Group two is formed by patients with osteochondria , spinal disc herniation and nerval compression. Both groups of patients undergo surgery, as they are suffering from pain (e.g. kyphoplasty, nucleotomy, spondylodesis, decompression). In order to differentiate between chronic nociceptive pain and chronic neuropathic pain in these two groups the painDetect questionnaire is used. To examine the severity of disability in the patients' everyday life the Roland-Morris Disability questionnaire is used. The included patients are examined and seen preoperative, postoperative before discharge from hospital, 6 weeks and 6 months after surgery.

Official Title
-----------------
Study of Different Types of Pains in Groups of Patients With Different Diagnoses of Degenerative Diseases and Their Related Surgeries

Conditions
-----------------
Ache

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Backache because of degenerative diseases Surgery is necessary Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1 Fracture of vertebra<br>Osteoporotic fracture of the vertebra | |
| 2 Nerve Compression<br>Osteochondria, Spinal disc herniation, Nerve compression | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Backache objectified by the PainDETECT Questionnaire |  | 6 months |
Study on Serum Zinc and Selenium Levels in Epileptic Patients

Study Overview
=================
Brief Summary
-----------------
This study was carried out with the purpose of evaluating zinc and selenium levels in serum of epileptic patients and compare with normal individuals.

Detailed Description
-----------------
Forty patients aged 18 to 50 years visiting Vali-Asr hospital in Arak, I.R. Iran, who were diagnosed with generalized form of epilepsy by a neurologist for the first time were recruited as cases. The control group (n=40) was selected from healthy individuals, in whom no disease was diagnosed until this study, and were matched to the case group by age, sex, and economical status.

Official Title
-----------------
Arak University of Medical Sciences , Ministry of Health and Education,I.R.Iran

Conditions
-----------------
Generalized Epileptic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: New generalized and single epileptic cases patients who accept and sign the approval form of ethical committee non smoker, no trauma, no use of selenium supplement, no use of zinc supplement, no use of vitamin A supplement, no use of vitamin D supplement, no Weight loss, no Diarrhea, no addiction, no alcohol consumption, no use of certain medications, Exclusion Criteria: presence of above criteria as well as, generalized and single epileptic cases under treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Zinc level (micro gram per deciliter)<br>In all cases | |
| Selenium level (micro gram per deciliter)<br>In all cases | |
| Zinc level in male (micro gram per deciliter)<br> | |
| Selenium level in male (micro gram per deciliter)<br> | |
| Zinc level in Female (micro gram per decilitre)<br> | |
| Selenium level in Female (micro gram per decilitre)<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study on Serum Zinc and Selenium Levels in Epileptic Patients | decrement in serum zinc and selenium level | 5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison between the selenium levels by gender in two groups |  | 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
zinc, selenium, serum, epilepsy, antioxidants
Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally Study

Study Overview
=================
Brief Summary
-----------------
This study aims to validate the efficacy and safety of subthreshold laser photocoagulation on high-risk macular drusen in early age-related macular degeneration which has a high risk of conversion to exudative AMD.

Detailed Description
-----------------
SAVE Study (Stop Early Age-related Macular Degeneration form Vision Loss Eternally)

Official Title
-----------------
Focal Subthreshold Laser Treatment for Macular Drusen

Conditions
-----------------
Age-Related Macular Degeneration, Retinal Drusen

Intervention / Treatment
-----------------
* Procedure: Subthreshold Laser Photocoagulation
* Drug: intravitreal Anti-VEGF injection
* Device: Subthreshold Laser


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Drusen in both eyes examined under fundoscopy At least one of the eyes must have high-risk soft drusen BCVA below ETDRS 83 letters Patient with consent to participate Exclusion Criteria: Prior diagnosis with choroidal neovascularization Exudative AMD in at least one eye If the patient has only one visually effective eye (last eye) Other macula or retinal diseases than age-related macular degeneration

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention-Device:_Laser<br>Subthreshold focal photocoagulation Intravitreal Anti-vascular endothelial growth factor (Anti-VEGF) injection | Procedure: Subthreshold Laser Photocoagulation<br>* Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen<br>Drug: intravitreal Anti-VEGF injection<br>* To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.<br>Device: Subthreshold Laser<br> <br> |
| No Intervention: Control<br>Contralateral eye | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in drusen size |  | 3 month interval | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best Corrected Visual Acuity (BCVA) | ETDRS and Snellen visual acuity measurement | 3 months interval | 
| Change in drusen distribution |  | 3 month interval | 
| Change in autofluorescence |  | 3 month interval | 
| Choroidal Neovascularization |  | 3 months interval | 
| Contrast Sensitivity | Contrast Sensitivity Test | 3 months interval |
Study on the Occurrence of Head and Neck Cancers During Pregnancy

Study Overview
=================
Brief Summary
-----------------
Head and neck cancers that occurred during pregnancy

Official Title
-----------------
Study on the Occurrence of Head and Neck Cancers During Pregnancy

Conditions
-----------------
Head and Neck Cancer, Pregnancy Related

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 year old woman or over at the time of participation PS 0 -2 Cancer diagnosed (biopsy date) from 01/01/2010 between the second week of pregnancy and the 12 months postpartum. Primitive may concern the following sites: oral cavity, nasopharynx, oropharynx, hypopharynx, larynx, prevalent lymphadenopathy, nasal cavity, salivary glands, dental tumors, ear tumors, paragangliomas optic pathways, facial sinus / facial mass, nose, ear and other head and neck All histologies (epithelial tumors, sarcomas, mucosal melanomas, embryonic tumors, undifferentiated tumors) Patient receiving or having received a specific oncological treatment among surgery, radiotherapy, chemotherapy, hormone therapy. All stages allowed: localized stages and metastatic stages immediately. No opposition of the patient to participate in this study Exclusion Criteria: Any other neoplastic antecedent Exclusion of metastases at the level of the VADS of another primitive than a cancer of the VADS Exclusion of hematological tumors (lymphoma) and glial tumors Person subject to a legal protection measure or unable to express their consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serological status of patients | Number of patients with positive or negative serological status for PVH (Papilloma Virus Humain) and EBV (Epstein-Barr Virus) | Through study completion, an average of 5 years | 
| Characteristics pregnancy of patients | Presence or absence of maternal-fetal diseases | Through study completion, an average of 5 years | 
| Tumor characteristics of patients | Histological type of cancer | Through study completion, an average of 5 years | 
| Tumor characteristics of patients | Localization of cancer | Through study completion, an average of 5 years |
Analysis of the Availability of the Treatments for ACE-I and ARB-induced Angioedema

Study Overview
=================
Brief Summary
-----------------
Specific treatments for angiotensin-converting-enzyme inhibitor (ACE-I) and angiotensin-receptor-blocker (ARB)-induced angioedema exist. Early access to these treatments is challenging because they are expensive and have short shelf lives making it illusory that all emergency department (ED) stock them. The aim of this retrospective study was to define, for each patient with a confirmed ACE-I or ARB-induced angioedema, at which step of the care, the specific treatment was administered. The second objective was to analyse the availability of these treatment in the area around Lyon, France and the factors that may influence it.

Official Title
-----------------
Efficient Treatments for ACE-I and ARB-induced Angioedema Exist and Should be Available to All Patients. Analysis of Their Availability and Influencing Factors in the Area Around Lyon, France

Conditions
-----------------
ACE-I and ARB-induced Angioedema.

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Every patient followed for the first time in our reference center for severe confirmed ACE-I or ARB-induced angioedema. Data were analyzed from patients attended either in a specialized angioedema consultation or during a hospitalization in our intensive care unit. Severe attack was defined either by its localization over the shoulder or by an severe abdominal attack. Exclusion Criteria: - Patients which received no specific treatment (icatibant, C1-inhibitor concentrate) were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years


Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Step of the care allowing the patients to benefit from a specific treatment. | Three answers are possible. Patients were treated with the specific medication (icatibant or C1-inhibitor concentrate) either in the first ED or by the medical ambulance team, or by the investigators reference center's intensive care unit. | October 2010 to December 2014 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Epidemiological characteristics | The investigators collect data such as age, sex, localization of the angioedema. | October 2010 to December 2014 | 
| Triggering treatments | The investigators detail which ACE-inhibitor, which ARB and eventually which co-medication was taken and triggered the angioedema. | October 2010 to December 2014 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Angioedema, Emergency treatment, Treatment availability, Health Equity
Genetic Mutation in Epithelial Ovarian Cancer

Study Overview
=================
Brief Summary
-----------------
Little is known about the characteristics of genetic mutation in a large multi-gene panel in epithelial ovarian cancer. This study is to explore the targeted genetic mutations via a multi-gene panel, which consists of more than 500 hundred genes. The mutation characteristics are to be revealed in single nucleotide variants, copy number variations, insertion-deletion variations, and genomic structural variations. The total mutation burden (TMB) will be calculated. The status of microsatellite instability, expression of PD-1 and PD-L1 antibodies are also tested. These findings will be studies in association with the patients' prognosis and sensitivity to platinum-based chemotherapy.

Official Title
-----------------
Overall Perspective on the Characteristics of Genetic Mutation in Chinese Patients of Epithelial Ovarian Cancer

Conditions
-----------------
Epithelial Ovarian Cancer, Nucleotide Variant, Copy Number Variation, Insertion-deletion Variation, Genomic Structural Variation, Total Mutation Burden, Microsatellite Instability, PD-1, PD-L1

Intervention / Treatment
-----------------
* Diagnostic Test: A multi-gene panel testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 years or older Pathology confirmed of recurrent cervical adenocarcinoma, squamous carcinoma or adenosquamous carcinoma With available materials for analysis With detailed clinicopathological information Given consent to participate the trial Exclusion Criteria: Not meeting all of the inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: A multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of genetic mutations | Frequency of various genetic mutations among recruited patients | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total mutation burden | Total mutation burden calculated in definite patient | Two years | 
| Frequency of microsatellite Instability | Microsatellite Instability in definite patient | Two years | 
| Expression rates of PD-1 and PD-L1 antibodies | Expression rates of PD-1 and PD-L1 antibodies among recruited patients | Two years |